Immunocore, Ltd.

Amgen, Inc. ’s Imdelltra (tarlatamab) for extensive-stage small cell lung cancer (ES-SCLC) is one of only two bispecific T-cell engagers (BiTEs) approved in the US to treat solid tumors. As additional

Just over a decade after Simon Westbrook bought a promising non-addictive he had developed from former employer Pfizer Inc. , the company he formed – Levicept Ltd – has posted promising mid-stage da

The number of biopharma initial public offerings in the US in 2024 grew to four with IPOs by Alto Neuroscience Inc. and Fractyl Health , showing that investors continue to be supportive of certain

If the J.P. Morgan Healthcare Conference is a bellwether for the year ahead, 2024 could be on track to be an improvement over 2023 for the biopharma sector. Drug makers, investors and other health car